1.
Geissler K, Jäger E, Barna A, Sliwa T, Knöbl P, Schwarzinger I, Gisslinger H, Valent P. Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?. Haematologica 2016; 101(12):e492-e492; https://doi.org/10.3324/haematol.2016.156448.